Romeo: “Fenfluramine is a great possibility for patients resistant to therapies”

Antonino Romeo, Primary Emeritus of the UOC Pediatric Neurology and Regional Center for Epilepsy of the Fatebenefratelli Hospital in Milan, is one of the experts who participated in the press conference with which the reimbursement of UCB’s new drug based on fenfluramine, indicated in the treatment of seizures associated with Dravet Syndrome. Romeo illustrates the clinical features of the syndrome and explains in which patients the use of fenfluramine is indicated.